Stevanato Group Spa
Research Stevanato Group Spa (STVN) on Bullrun: valuation model: 1.8% overvalued, market cap USD 6.20B, P/E 39.5, dividend yield 0.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSTVN
- ExchangeNYSE
- CountryItaly
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencyUSD
- Valuation signal1.8% overvalued
- Market capUSD 6.20B
- P/E39.5
- Dividend yield0.3%
- Financial periodQ2 2026
- RevenueEUR 302.00M
- Net incomeEUR 22.96M
- Free cash flow-EUR 33.87M
- Gross margin28.7%
Valuation Snapshot
Bullrun's latest valuation model marks Stevanato Group Spa as 1.8% overvalued; latest market cap is USD 6.20B; P/E is 39.5; dividend yield is 0.3%.
Peer valuation comparison
Latest P/E is 39.46x versus a Healthcare sector median of 24.46x (61.3% above).
Latest dividend yield is 0.28% versus a Healthcare sector median of 2.11% (86.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 1.19B | EUR 139.84M | EUR 11.05M | 29.0% | 0.51 | EUR 130.60M | EUR 468.91M | EUR 1.49B |
| FY2024 | EUR 1.10B | EUR 117.82M | -EUR 85.66M | 27.4% | 0.44 | EUR 98.27M | EUR 428.97M | EUR 1.40B |
| FY2023 | n/a | n/a | n/a | n/a | 0.93 | EUR 69.60M | EUR 396.59M | EUR 1.13B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 6.20B | 39.5 | 0.3% | 0.06 |
| 2025 | 2025-12-31 | USD 5.49B | 34.7 | n/a | n/a |
| 2024 | 2024-12-31 | USD 5.95B | 46.4 | 0.3% | 0.06 |
| 2023 | 2023-12-29 | USD 7.24B | 45.5 | n/a | n/a |
| 2022 | 2022-12-30 | USD 4.76B | 31.5 | n/a | n/a |
| 2021 | 2021-12-31 | USD 5.94B | 37.4 | n/a | n/a |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.06 USD, yield 0.3%.
About Stevanato Group Spa
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Stevanato Group Spa overvalued or undervalued?
Bullrun's valuation model currently marks Stevanato Group Spa as 1.8% overvalued.
What is Stevanato Group Spa's market cap?
Stevanato Group Spa's market capitalization is USD 6.20B.
What is Stevanato Group Spa's P/E ratio?
Stevanato Group Spa's price-to-earnings (P/E) ratio is 39.5.
Does Stevanato Group Spa pay a dividend?
Stevanato Group Spa has a dividend yield of 0.3%.
What does Stevanato Group Spa do?
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.